Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) announced clinical trial data to reaffirm the effectiveness and safety of their messenger RNA-based COVID shots on Tuesday after President Donald Trump ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary ...

Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among ...

Vaccine experts told STAT that the data Moderna released May 18 from its phase I vaccine trial isn’t enough to show whether or not the vaccine will be effective. Moderna released data from an early ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...